Vanderbilt to host symposium on bone marrow disordersSep. 14, 2017, 9:22 AM
Vanderbilt University Medical Center (VUMC) clinicians will host an educational symposium on bone marrow disorders, including bone marrow failure, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), on Friday, Oct. 13, from 11:30 a.m. – 6 p.m. at the Omni Nashville Hotel, 250 5th Ave. South.
The free symposium for health care practitioners is sponsored by VUMC and the Aplastic Anemia and MDS International Foundation.
Bone marrow disease specialists from VUMC and other leading medical centers will provide the latest information on the diagnosis and management of bone marrow failure and myeloid malignancies based on current clinical practice guidelines and recent research studies and will provide insight into these rare disorders and offer recommendations for clinical practice.
“This is a unique opportunity for our local and referring medical communities to hear about exciting new drug approvals and treatment considerations specifically for myeloid cancers and bone marrow failure,” said course director Michael Savona, M.D., associate professor of Medicine and director of Hematology Research at VUMC.
The educational sessions are appropriate for health care professionals working with patients with leukemia, MDS and other bone marrow failure, including hematologists, advance practice providers, oncologists, primary care physicians, pediatricians, pathologists, residents/fellows, physician assistants, nurses and nurse practitioners and pharmacists. The activity is approved for continuing medical education (CME) credits.
VUMC faculty include Stephen Strickland Jr., M.D., MSCI, assistant professor of Medicine and clinical director of Acute Leukemia, who will discuss newly approved therapy for AML; Michael Byrne, D.O., assistant professor of Medicine, who will review post-hematopoietic stem cell transplant relapse in AML; and Tamara Moyo, M.D., Ph.D., instructor of Medicine, who will discuss bone marrow failure and the role of stem cell transplant in patients with bone marrow failure.
They will be joined by Daniel Pollyea, M.D., M.S., clinical director of Leukemia Services at the University of Colorado School of Medicine, who will highlight new therapies including BCL-2 inhibitors; Mrinal Patnaik, MBBS, assistant professor of Medicine at the Mayo Clinic, who will review strategies for overlaps syndromes (such as CMML) that have properties of both MDS and myeloproliferative neoplasms; and Amy DeZern, M.D., MHS, assistant professor of Medicine at Johns Hopkins School of Medicine, who will discuss the different types of myelodysplastic syndromes.